OCUL FY2025 SEC EDGAR DEF 14A #26 of 168 in industry

Ocular Therapeutix, Inc CEO pay ratio

The CEO earned $247K in FY2025 against median worker pay of $247,396 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-30
Industry
Chemicals & Pharmaceuticals
Industry rank
#26/168

Data updated August 2026

Subscribe to Ocular Therapeutix, Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
145:1
Moderate (Scale: 0–1000:1)
CEO pay
$247K
Median worker
$247,396

Answer first

Ocular Therapeutix, Inc's FY2025 CEO total of $247K ranks #1318 of 1,423 complete filings; its 145:1 pay ratio ranks #454. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $247,396. Industry placement uses the FY2025 SIC-28 peer cohort (# 26 of 168, 85th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1318
$247K of 1,423 FY2025
Ratio rank
#454
145:1 of 1,423
Industry pct
85th
top quartile of industry peers by pay ratio

How Ocular Therapeutix, Inc ranks nationally

Ocular Therapeutix, Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$247,396 7th percentile higher than 7% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Ocular Therapeutix, Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($247K) against pay ratio (145:1) for Ocular Therapeutix, Inc (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both06949744.513899489.120849233.627798978.136.4:167.2:198:1128.8:1159.6:1CEO total payPay ratio (CEO : median worker)Ocular Therapeutix, Inc, CEO total pay: 247396 · Pay ratio (CEO : median worker): 145:1Ocular Therapeutix, IncLyondellBasell Industries N.V., CEO total pay: 110140 · Pay ratio (CEO : median worker): 141:1LyondellBasell Industries N.V.Element Solutions Inc, CEO total pay: 26480462 · Pay ratio (CEO : median worker): 153:1Element Solutions IncFuller H B Co, CEO total pay: 8830569 · Pay ratio (CEO : median worker): 137:1Fuller H B CoQuidelOrtho Corp, CEO total pay: 11290664 · Pay ratio (CEO : median worker): 154:1QuidelOrtho Corp
Ocular Therapeutix, Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Ocular Therapeutix, Inc's structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
145:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$247K
Companies in Industry
168
vs. Industry Median
Above
#26 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Ocular Therapeutix, Inc: MID · MICRO pay ratio

Ocular Therapeutix, Inc's FY2025 ratio 145:1 ranks #26 of 168 Chemicals & Pharmaceuticals filers (85th percentile). the CEO earned 145× the median employee ($247,396) in FY2025.

Median employee $247,396 (ELITE-MED); MID · MICRO stamps put about 145 median-wage years per CEO year.

CEO Total Pay

$247K

FY2025 Summary Compensation, below median

Pay Ratio

145:1

Near industry median

Ocular Therapeutix, Inc in the higher Chemicals & Pharmaceuticals third

Ocular Therapeutix, Inc's FY2025 ratio 145:1 ranks #26 of 168 Chemicals & Pharmaceuticals filers (85th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Ocular Therapeutix, Inc's $247K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1318 and ratio rank #454 split - treat 145:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$247K
Median Employee Pay
$247,396
Pay Ratio
145:1
Filing Date
2026-04-30

Company Info

Ticker
OCUL
CIK
1393434
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1393434, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Ocular Therapeutix, Inc's FY2025 ratio 145:1 ranks #26 of 168 Chemicals & Pharmaceuticals filers (85th percentile).

Read with Ocular Therapeutix, Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · MICRO · ELITE-MED.

Capital Southwest Corp · MICRO

ABS(ceo_total_comp) peer at $255K (Δ $8K heavier vs Ocular Therapeutix, Inc); FLOOR · ELITE-MED vs this page's MID · MICRO · ELITE-MED.
Box Inc · MICRO

ABS(ceo_total_comp) peer at $257K (Δ $10K heavier vs Ocular Therapeutix, Inc); MODEST · ELITE-MED vs this page's MID · MICRO · ELITE-MED.
APA Corp · MICRO

ABS(ceo_total_comp) peer at $238K (Δ $10K lighter vs Ocular Therapeutix, Inc); MODEST · ELITE-MED vs this page's MID · MICRO · ELITE-MED.
Moelis & Co · MICRO

ABS(ceo_total_comp) peer at $260K (Δ $13K heavier vs Ocular Therapeutix, Inc); FLOOR · ELITE-MED vs this page's MID · MICRO · ELITE-MED.
Indivior Pharmaceuticals, Inc. (SIC 28 pole)

Indivior Pharmaceuticals, Inc. stamps MID · UNFILED nearest in-SIC by ABS(pay_ratio) to Ocular Therapeutix, Inc's MID filing.
National dual ranks · #1318/#454

Ocular Therapeutix, Inc's FY2025 package sits #1318 by CEO dollars and #454 by ratio under MICRO · MID.
Pay-equity trends · MID

Ocular Therapeutix, Inc's MID · ELITE-MED stamps sit mid-band - pay-equity trends place the ratio against workforce pay.
Data sourced from SEC EDGAR DEF 14A for Ocular Therapeutix, Inc (CIK 1393434), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.